What Is NAD+?
NAD+ (nicotinamide adenine dinucleotide) is a dinucleotide coenzyme found in all living cells. It consists of two nucleotides — adenine and nicotinamide — joined by a pair of phosphate groups. NAD+ exists in two interconvertible redox forms:- NAD+ (oxidized form) — accepts electrons and becomes NADH
- NADH (reduced form) — donates electrons back to the electron transport chain
This NAD+/NADH redox cycling is central to the energy-extracting reactions of glycolysis, the citric acid cycle, and mitochondrial oxidative phosphorylation. Beyond its redox carrier role, NAD+ is a direct co-substrate — consumed and regenerated — for a set of regulatory enzymes whose activity is rate-limited by cellular NAD+ concentration.
Biosynthesis Pathways
Cells maintain NAD+ through three overlapping pathways:
Salvage pathway (primary)
The dominant route in most mammalian cells. The enzyme NAMPT (nicotinamide phosphoribosyltransferase) converts nicotinamide (a breakdown product of NAD+ consumption) back to nicotinamide mononucleotide (NMN), which is then adenylated by NMNAT enzymes to regenerate NAD+. NAMPT is the rate-limiting enzyme in this cycle; its expression and activity are major determinants of cellular NAD+ levels.
De novo synthesis from tryptophan
The kynurenine pathway converts dietary tryptophan to quinolinic acid and then to NAD+ via the Preiss-Handler pathway. This pathway is quantitatively minor in most tissues under normal conditions but becomes relevant in immune activation and inflammatory states.
Preiss-Handler pathway (from nicotinic acid)
Nicotinic acid (niacin) is converted to NAD+ via nicotinic acid mononucleotide (NAMN). This pathway bypasses NAMPT and is used as an alternative NAD+ repletion route in research settings.
NMN and NR as research precursors:Published research has examined NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) as cell-permeable precursors that feed into the salvage pathway downstream of NAMPT. Both compounds have been used in animal studies as tools to elevate intracellular NAD+ levels above baseline, allowing researchers to probe the downstream effects of NAD+ availability on SIRT and PARP pathway activity.
Key NAD+-Consuming Enzymes
Unlike most coenzymes, NAD+ is not simply recycled as a hydrogen carrier — it is also stoichiometrically consumed (cleaved) by a group of enzymes that use it as a co-substrate. The major NAD+ consumers are:
Sirtuins (SIRT1–SIRT7)
Sirtuins are a family of NAD+-dependent protein deacylases that remove acetyl groups from lysine residues on target proteins. The deacylation reaction cleaves NAD+ to nicotinamide and O-acetyl-ADP-ribose. Key members include:
- SIRT1 — nuclear/cytoplasmic; deacetylates and activates PGC-1α (mitochondrial biogenesis), FOXO transcription factors, and p53; studied in metabolic and longevity research models
- SIRT3 — mitochondrial; deacetylates and activates mitochondrial metabolic enzymes; associated with mitochondrial function in caloric restriction research
- SIRT6 — nuclear; involved in DNA repair and telomere maintenance; deacetylates H3K9ac and H3K56ac at sites of DNA damage
Because sirtuin activity is directly proportional to NAD+ concentration at physiological levels, cellular NAD+ availability functions as a metabolic sensor that gates sirtuin-mediated regulatory programs.
PARP enzymes (PARP1, PARP2)
PARP1 (poly-ADP-ribose polymerase 1) is a DNA repair enzyme that detects single-strand breaks and responds by synthesizing poly-ADP-ribose (PAR) chains on target proteins using NAD+ as the ADP-ribose donor. Each strand-break signaling event consumes a significant number of NAD+ molecules. Under conditions of high DNA damage load, PARP1 activity can deplete cellular NAD+ substantially, creating a linkage between DNA damage levels, NAD+ availability, and downstream SIRT1/SIRT3 activity.Published studies have used PARP inhibitors as research tools to examine the NAD+–PARP–SIRT axis, demonstrating that blocking PARP-mediated NAD+ consumption can restore SIRT1 activity in models of NAD+ depletion.
CD38
CD38 is an ectoenzyme and the dominant NADase in mammalian tissues — responsible for the majority of NAD+ hydrolysis outside the SIRT/PARP pathways. CD38 expression increases with age in multiple published datasets, making it a candidate contributor to age-associated NAD+ decline. Published animal studies have demonstrated that CD38 knockout mice maintain elevated tissue NAD+ levels into old age.NAD+ Decline in Cellular Aging Research
A consistent finding across published literature is that NAD+ levels in tissues — measured in animal models and in human biopsies — decline progressively with age. Proposed mechanisms include:
- Reduced NAMPT expression — limiting the salvage pathway's recycling capacity
- Increased CD38 activity — accelerating non-productive NAD+ hydrolysis
- Increased PARP activity — reflecting higher DNA damage accumulation with age
- Mitochondrial dysfunction — disrupting the NAD+/NADH redox balance
The functional consequence of NAD+ decline, in research framing, is reduced activity of NAD+-dependent regulatory enzymes — particularly SIRT1, SIRT3, and SIRT6 — which are implicated in mitochondrial biogenesis, DNA repair efficiency, and metabolic homeostasis in published aging-biology literature.
This framing has motivated a substantial body of research using NAD+ precursors (NMN, NR) and CD38 inhibitors as experimental tools to probe whether restoring NAD+ levels in aged cells or animals reverses associated functional deficits. Results in animal models have been broadly positive; human data remain more limited and are under active investigation.
Research Applications
Mitochondrial function studies
NAD+ is studied as a modulator of mitochondrial biogenesis through the SIRT1–PGC-1α axis. Published animal studies demonstrate that elevating NAD+ increases PGC-1α deacetylation and activation, stimulating mitochondrial gene expression programs. For related mitochondrial-derived peptide research, see MOTS-c, which activates AMPK through a complementary pathway.
Cellular senescence and aging models
Multiple published studies use NAD+ repletion strategies (NMN, NR) to probe functional outcomes in senescence models — including changes in SASP (senescence-associated secretory phenotype), telomere maintenance (via SIRT6), and metabolic flexibility. For a distinct longevity-focused research agent from the same category, see Epitalon, which targets telomerase activation through a different mechanism.
Metabolic research
SIRT1 deacetylates and activates downstream metabolic regulators involved in glucose homeostasis and fatty acid oxidation. NAD+ availability has been examined as a regulator of these pathways in diet-induced metabolic stress models in rodents.
DNA repair research
PARP1 activation kinetics and NAD+ depletion following controlled DNA damage are used as quantitative readouts of DNA repair pathway function in cell culture models.
Dose Form and Handling
NAD+ is supplied as a crystalline powder (free acid or sodium salt form). It is water-soluble and reconstitutes readily in aqueous buffers or bacteriostatic water.
- Storage (powder, lyophilized/crystalline): −20 °C; stable for 12–24 months; protect from moisture and light
- Storage (reconstituted): 2–8 °C; use within 2–4 weeks; aliquot for longer storage to minimize freeze-thaw cycles
- pH sensitivity: NAD+ is stable in neutral to mildly acidic buffers; avoid strongly alkaline conditions which accelerate hydrolysis of the glycosidic bond
See our reconstitution guide and storage guide for standard handling procedures applicable to all soluble research compounds.
Frequently Asked Questions
Is NAD+ technically a peptide?No. NAD+ is a dinucleotide coenzyme rather than a peptide or protein. It is stocked alongside research peptides because it is used in closely related cellular and longevity research workflows — particularly those involving mitochondrial function and SIRT pathway modulation — and is often purchased by the same research groups.
What is the relationship between NAD+ and NMN or NR?NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are NAD+ precursors that enter the salvage biosynthesis pathway at different points. In research settings, they are used as tools to increase intracellular NAD+ concentration in cell culture or animal experiments, allowing downstream SIRT and PARP pathway activity to be studied at elevated NAD+ levels.
How does NAD+ decline relate to aging research?Published studies in rodent models and human tissue biopsies consistently report lower NAD+ levels in aged tissues compared to younger comparators. Proposed mechanisms include increased CD38 activity, reduced NAMPT expression, and higher PARP activation from accumulated DNA damage. Research using NAD+ precursors examines whether restoring NAD+ availability can reverse associated functional markers in these aging models.
What enzymes consume NAD+?The primary NAD+-consuming enzymes studied in the literature are SIRT1–SIRT7 (protein deacylases), PARP1/PARP2 (DNA repair), and CD38 (a major NADase that hydrolyzes NAD+ to ADP-ribose). Collectively, these enzymes establish NAD+ as a regulatory co-substrate whose intracellular concentration directly governs the activity of multiple signaling networks.
Product Availability
Phase 1 Peptides stocks NAD+ at 99%+ purity with third-party laboratory documentation:
- NAD+ — research-grade, multiple dose sizes
Summary
NAD+ (nicotinamide adenine dinucleotide) functions both as a redox carrier essential to cellular energy metabolism and as a direct co-substrate consumed by a set of regulatory enzymes — sirtuins, PARP, and CD38 — whose activity is gated by cellular NAD+ concentration. The NAMPT-driven salvage pathway is the primary route for NAD+ recycling; its rate-limiting nature makes NAD+ availability a functional sensor of metabolic state. Age-associated NAD+ decline, documented across multiple published datasets, has motivated research into NMN and NR as precursor tools for studying SIRT and PARP pathway function at elevated NAD+ levels in cellular and animal models. Researchers interested in modulating NAD+ availability through a different mechanism — inhibiting the competing enzyme (NNMT) that consumes nicotinamide before it enters the salvage pathway — may also see the 5-Amino-1MQ research primer. For a side-by-side comparison of the four primary mitochondria-focused research compounds, see the Mitochondrial Research Compounds overview.
All Phase 1 Peptides products are supplied exclusively for laboratory research and in vitro studies. They are not intended for human or animal consumption, clinical use, or therapeutic application.